CTRI/2021/08/035812进行中（未招募）未知
CYP2D6 gene as a biomarker for predicting the dose of ondansetron for PONV prophylaxis in patients undergoing laparoscopic cholecystectomy- a prospective observational study.
niversity College of Medical Sciences and GTB Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients with ASA physical status I or II undergoing laparoscopic cholecystectomy under GA.
排除标准
- •Pregnant patients; BMI > 35 kg/m²; Patients having history of significant cardiac, hepatic or renal disease; Patients having nausea or vomiting 24 hours before surgery and/or those receiving any other antiemetics within last 24 hours; Patients on any potential CYP2D6 inhibitors for e.g., beta-adrenergic blocking agents, TCAs, antiarrhythmic 1c class drugs, debrisoquine, codeine or dextromethorphan; & patients with known hypersensitivity to 5HT3 agents.
研究者
相似试验
进行中（未招募）
1 期
Development of CYP2D6 genotype based dosage guidelines for the beta-blockers metoprolol and carvedilol based on hepatic clearance and resting and exercise heart rate reduction - MCCDHealthy male and female volunteersEUCTR2004-002754-62-DEniversity of Göttingen; Dep. of Clinical Pharmacology131
Unknown
不适用
Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on TamoxifenBreast Cancer FemaleNCT03504631Trisakti University117
已完成
不适用
Biomarkers of CYP2D6 and CYP3A4 Variability in PediatricsDrug Metabolism PhenotypeNCT01118858Children's Mercy Hospital Kansas City205
已完成
2 期
Clinical validation of a CYP2B6 pharmacogenetics test and dosing algorithm in the safe and efficacious use of Efavirenz and its cost effective & benefit analysis in a public healthcare settingPACTR202105618971235260
已完成
不适用
Cohort Study to Assess the Impact of CYP2D6 Genotype on the Efficacy ofClomipheneN97.9Female infertility, unspecifiedDRKS00010070Robert Bosch Gesellschaft für Medizinische Forschung mbH161